Sun Pharma Q4 Results: Net profit up 33.7% to ₹1,984.4 crore, dividend declared

Revenue from operations rose 10.1% to ₹11,811.3 crore in Q4 FY24, compared to ₹10,725.5 crore in the corresponding period last year.

Sun Pharma's EBITDA (earnings before interest, taxes, depreciation, and amortisation) for the quarter under review stood at ₹3,034 crore, while the margin was 25.3%.

The company's board recommended a final dividend of ₹5 per share of ₹l each, subject to shareholders' approval.

The pharma giant also appointed Dilip Shanghvi, Managing Director (MD) of the company, as Chairman of the board with immediate effect.

For the entire FY24, the net profit increased 13% to ₹9,576.3 crore, while the revenue from operations jumped 10.3% to ₹47,758.4 crore.

The stock closed 1.5% higher at ₹1,564 on the NSE after the announcement of Q4 results.

The US formulation sales were reported at $476 million, up 10.9% year-on-year.